newsfilter
← Latest News
GlobeNewswire·

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company